In conclusion, our results shed light into the differential effects of a long-acting GLP-1R agonist in improving NAFLD and PLF in the context of obesity and leaness, but decreasing liver mass recovery after PH. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.